NCT02091999 - A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | Biotech Hunter

Enrollment

213

Participants

Timeline

Start Date

May 14, 2014

Primary Completion Date

December 7, 2022

Study Completion Date

December 7, 2022

Conditions

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

Interventions

DRUG

enfortumab vedotin

intravenous (IV) infusion

Trial Locations (21)

10029

Site US00018, New York

10065

Site US00002, New York

15232

Site US00020, Pittsburgh

19111

Site US00013, Philadelphia

22031

Site US00024, Fairfax

27599

Site US00023, Chapel Hill

33136

Site US00007, Miami

33612

Site US00008, Tampa

48109

Site US00005, Ann Arbor

48201

Site US00003, Detroit

53226

Site US00015, Milwaukee

53792

Site US00009, Madison

66205

Site US00004, Fairway

80045

Site US00017, Aurora

89119

Site US00021, Las Vegas

90033

Site US00012, Los Angeles

94305

Site US00019, Stanford

06520

Site US00006, New Haven

T2N 4N2

Site CA00011, Calgary

T6G 1Z2

Site CA00001, Edmonton

M5G 2M9

Site CA00010, Toronto

All Listed Sponsors

collaborator

Seagen Inc.

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY